Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics. Expanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.
Patients admitted to the hospital with infections are often treated with intravenous antibiotics. The rationale for using intravenous antibiotics includes eliminating the risk of reduced absorption, achieving higher serum concentrations, and the fact that many broad-spectrum antibiotics (such as cephalosporins and carbapenems) are not available in oral form. However, intravenous antibiotics also have drawbacks, such as the risk of catheter-related infections, challenges in home-based treatment, and difficulty switching to oral antibiotics unless microbiological results are definitively positive. Prolonged hospital stays associated with intravenous antibiotic treatment lead to economic burdens, increased risk of hospital-acquired infections, and significant functional decline, especially in older patients. In recent decades, many studies have explored the possibility of fully or partially replacing intravenous antibiotics with oral antibiotics for certain infections. In this study, the investigators will examine the safety and efficacy of primarily oral antibiotic regimens in patients with confirmed or suspected infections admitted to the emergency department. The study is an open-label, prospective, randomized controlled trial. Participants will be randomly assigned to receive either standard intravenous antibiotic treatment according to Danish guidelines or oral antibiotic treatment based on tailored recommendations developed by microbiologists and infectious disease specialists at participating sites, in accordance with local guidelines. The study has two primary outcomes: 1) Efficacy-measured as the number of days alive outside the hospital within 30 days after randomization, and 2) Safety-measured by mortality or the need for vasopressors within 30 days after randomization. A total of 4,000 patients will be needed to address both primary outcomes. Aim: The trial aims to investigate the safety and efficacy of oral antibiotic administration compared to intravenous antibiotic administration in patients referred to the emergency department with suspected or diagnosed bacterial pneumonia, urinary tract infection and cellulitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
4,000
Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).
Sygehus Sønderjylland
Aabenraa, Southern Denmark, Denmark
RECRUITINGBispebjerg and Frederiksberg Hospital
Copenhagen, Denmark
ACTIVE_NOT_RECRUITINGNordsjællands Hospital
Copenhagen, Denmark
RECRUITINGEsbjerg and Grindsted Sygehus
Esbjerg, Denmark
RECRUITINGHerlev and Gentofte Hospital
Herlev, Denmark
ACTIVE_NOT_RECRUITINGAmager and Hvidovre Hospital
Hvidovre, Denmark
ACTIVE_NOT_RECRUITINGSygehus Lillebælt
Kolding, Denmark
RECRUITINGDays alive outside hospital (Efficacy)
The number of days the patients are alive outside hospital within 30 days after randomization
Time frame: From randomization date to 30 days
Number of patients requiring treatment with vasopressors
Number of patients that die or number of patients that require treatment with vasopressors within 30 days after randomization
Time frame: From date of randomization to 30 days
Length of hospital stay
Duration of hospital length of stay in days
Time frame: From date of randomization until date of documented hospital discharge or date of death from any cause, whichever came first, assessed up to 6 months
Inhospital mortality
The number of death measured inhospital before discharge
Time frame: From date of randomization until date of death in hospital from any cause, assessed up to 6 months
30-days mortality
The number of death within 30 days
Time frame: up to 30 days from baseline (randomization date)
90-days mortality
The number of death within 90 days
Time frame: Up to 90 days from baseline (randomization date)
One-year mortality
The number of death within one-year
Time frame: Up to one-year from baseline (randomization date)
Five-year mortality
The number of death within five-years
Time frame: Up to five-years from baseline (randomization date)
Discharge within 24 hours
The number of patients discharged within 24 hours
Time frame: Up to 24 hours after rom baseline (randomization date)
Readmission
The number of patients readmitted to hospital
Time frame: 30 days after discharge date
Intensive care admission
Number of patients admitted to intensive care during current hospital stay
Time frame: From date of randomization until date of admission to intensive care during hospitalization due to any cause, assessed up to 6 months
Days on antibiotic treatment within 30 days
Number of days the patient have been treated with antibiotics
Time frame: Within 30 days from randomization date
Bacteremia
Number of patients diagnosed with bacteremia
Time frame: Day 7 to day 30 from randomization date
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.